Mortality in the TRITON trial: Update from the FDA prasugrel action package

American Journal of Cardiology

Volumn 106, Issue 2, 2010, Pages 293-294

  Wiviott, Stephen D ^a   Antman, Elliott M ^a   Braunwald, Eugene ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

EID: 77955699516     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.04.004     Document Type: Letter

References (4)

1. V.L. Serebruany Mortality in the TRITON trial: update from the FDA prasugrel action package Am J Cardiol 105 2010 1356 1357
2. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, and E.M. Antman Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
3. United States Food and Drug Administration FDA approved drug products http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails Accessed October 22, 2009
4. E.F. Unger Weighing benefits and risksthe FDA's review of prasugrel N Engl J Med 361 2009 942 945